FORA Capital LLC Has $653,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

FORA Capital LLC raised its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 121.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 18,180 shares of the company’s stock after purchasing an additional 9,958 shares during the quarter. FORA Capital LLC’s holdings in Dyne Therapeutics were worth $653,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. FMR LLC boosted its holdings in Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the period. Vanguard Group Inc. grew its position in Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares in the last quarter. Jennison Associates LLC grew its position in Dyne Therapeutics by 1.5% during the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after buying an additional 19,730 shares in the last quarter. Federated Hermes Inc. grew its position in Dyne Therapeutics by 10.4% during the second quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock worth $42,881,000 after buying an additional 114,888 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after buying an additional 1,118,590 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Insider Activity

In related news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Cox bought 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. This trade represents a -133.33 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 176,257 shares of company stock valued at $6,193,718 in the last quarter. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Stock Up 6.5 %

Shares of DYN stock opened at $31.13 on Friday. Dyne Therapeutics, Inc. has a 12-month low of $10.12 and a 12-month high of $47.45. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -8.74 and a beta of 1.10. The firm has a fifty day moving average of $31.89 and a 200-day moving average of $35.39.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on DYN shares. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Guggenheim lifted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Royal Bank of Canada initiated coverage on Dyne Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $45.00 target price on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $50.82.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.